If you look at people with or without... T2D [type 2 diabetes], SGLT-2 inhibitors have been shown to decrease the risk of hospitalization and death for heart failure patients with reduced ejection fraction and improve basically all cardiovascular outcomes in patients with heart failure who have preserved EF.